Wanbury

Wanbury received approval from the European Directorate for the Quality of Medicines and Healthcare for its Rivaroxaban API, enabling it to serve customers in the European Union and other countries accepting CEP certification. It also received USFDA DMF clearances for Paroxetine HCl and Metformin HCl while ANDA reviews continued for multiple customers. APIs accounted for about 88% of the company’s latest disclosed revenue mix, and more than 80% of API sales came from exports. Wanbury reported operating revenue of ₹650.3 crore for FY26.

Powered by Tijori

July 30 (Reuters) - Wanbury Ltd WANB.NS:

• RECEIVES NO DMF DEFICIENCY LETTER FROM USFDA FOR MULTIPLE ANDAS

Source text: ID:nNSE7NzJLq

Further company coverage: WANB.NS

(([email protected];))

** Pharma company Wanbury's shares WANB.NS fall as much as 7.61%, their steepest intraday drop in six weeks, to 314.05 rupees; last down 3.3%

** U.S. drug regulator issued form 483 with six observations after routine good manufacturing practices inspection at WANB's Andhra Pradesh facility

** Form 483 flags conditions that may violate U.S. FDA standards; multiple observations can raise concerns over potential remediation costs, delays in approvals or escalation to stricter regulatory action if not resolved

** WANB says it will respond to these observations within the stipulated time

** YTD, WANB up about 45%

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Wanbury Limited's active pharmaceutical ingredient manufacturing site in Tanuku, Andhra Pradesh, underwent a routine cGMP inspection by the U.S. Food and Drug Administration from July 13 to July 17, 2026. At the conclusion, the agency issued a Form 483 with six observations. The company said it will respond to the observations within the stipulated timeframe and keep exchanges informed of further updates. The Tanuku facility had recently received a successful quality clearance from Australia's TGA.

Powered by Tijori

July 20 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY - USFDA INSPECTION AT TANUKU FACILITY CONDUCTED FROM JULY 13 TO 17

• WANBURY - USFDA ISSUES FORM 483 WITH SIX OBSERVATIONS AT TANUKU FACILITY

Source text: ID:nBSE9bct6S

Further company coverage: WANB.NS

(([email protected];))

Wanbury Limited's board passed a circular resolution on July 15, 2026, approving the early redemption in full of its 12.5% secured, guaranteed, non‑convertible debentures. The NCDs, originally issued in two tranches in February and October 2025 with a maturity date of February 28, 2030, have an outstanding principal of ₹180 crore. The company said the exact early redemption date will be mutually agreed with debenture holders and will occur prior to the original maturity, while the record date for the redemption was set as June 20, 2026. The repayment effectively eliminates a large chunk of Wanbury’s debt ahead of schedule.

Powered by Tijori

Catalyst Trusteeship, acting as debenture trustee, released a pledge on 85.2 lakh equity shares of Wanbury Limited held by Expert Chemicals (India) Private Limited. The release took effect on July 6, 2026, reducing the encumbered stake with the trustee from 34.93% of total voting capital to 10.54%.

Powered by Tijori

Wanbury Ltd. has received a successful quality inspection outcome from Australia's Therapeutic Goods Administration (TGA) at its API manufacturing site in Tanuku, Andhra Pradesh. The clearance brings the site closer to receiving a GMP certificate, which would enable the company to ship three additional active pharmaceutical ingredients to the Australian market. The company separately noted that its Patalganga site already received a GMP certificate from South Korea's MFDS following an inspection in April 2026, a milestone previously disclosed. Wanbury said it remains in cGMP compliance and committed to continual improvement across its manufacturing operations.

Powered by Tijori

June 10 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY - TANUKU API SITE COMPLETES TGA QUALITY INSPECTION

• WANBURY - GMP CERTIFICATE TO ENABLE WANBURY TO SHIP 3 ADDITIONAL APIS

Source text: ID:nNSEGqpxY

Further company coverage: WANB.NS

(([email protected];))

June 9 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY - EXPANDED REGULATORY SUBMISSION FOR NEW ACTIVE PHARMACEUTICAL INGREDIENTS

• WANBURY LTD - FOR DIPHENHYDRAMINE HCL, COMPANY SUBMITTED DMF TO MALAYSIA AND SINGAPORE

• WANBURY - TO SUBMIT DMFS FOR PAROXETINE HCL IN KOREA AND LATIN AMERICA

Source text: ID:nBSE6ZP8yc

Further company coverage: WANB.NS

(([email protected];;))

April 28 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY LTD - PATALGANGA SITE HAS COMPLETED KOREA FDA REGULATORY INSPECTION SUCCESSFULLY

Source text: ID:nBSEcbw68G

Further company coverage: WANB.NS

(([email protected];))

March 24 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY LTD - LAUNCHES CORIMINIC CPM DROPS FOR PEDIATRIC USE

• WANBURY LTD - LAUNCHES CORIMINIC NS NASAL DROPS FOR CHILDREN

Source text: ID:nNSELc6Vx

Further company coverage: WANB.NS

(([email protected];))

March 12 (Reuters) - Wanbury Ltd WANB.NS:

• RECEIVES SERTRALINE FORM II APPROVAL FROM ANVISA, BRAZIL

• RECEIVES APPROVAL FOR SPECIAL GRADE METFORMIN

Source text: ID:nBSE3w4BB

Further company coverage: WANB.NS

(([email protected];))

Jan 28 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY LTD - LAUNCHES COMMERCIAL PRODUCTION OF ANAESTHETIC API

• WANBURY LTD - NEW API TO GENERATE 180 MILLION RUPEES IN Q4 FY 2025-26

Source text: ID:nNSEbPzctS

Further company coverage: WANB.NS

(([email protected];))

** Wanbury's shares WANB.NS rise 9%, set for fifth straight session of gains

** Pharma co to launch two new products for formulation, including iron tablets and Ketamine

** Over 255,000 shares traded, 1.6x WANB's 30-day avg

** Stock has surged ~41% in March vs a ~10% rise in Nifty pharma index .NIPHARM

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Feb 12 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY LTD - TO ISSUE NCDS UP TO 2 BILLION RUPEES

Source text: ID:nBSE6vRkTp

Further company coverage: WANB.NS

(([email protected];))

Jan 3 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY - COMPLETES ANVISA AUDIT AT TANUKU PLANT

• WANBURY - FULL-FLEDGED MANUFACTURING OPERATIONS STARTED AT TANUKU PLANT

Source text: ID:nBSEbxM8RV

Further company coverage: WANB.NS

(([email protected];))

Dec 20 (Reuters) - Wanbury Ltd WANB.NS:

• TANUKU PLANT COMPLETES ANVISA INSPECTION

• INSPECTION COMPLETED WITH ZERO OBSERVATIONS FOR 5 APIS

Source text: ID:nBSE1W24Ym

Further company coverage: WANB.NS

(([email protected];;))

** Shares of Wanbury WANB.NS rise 4.45% to 218.49 rupees

** Pharma co gets establishment inspection report (EIR) from U.S. FDA for its Maharashtra facility

** Inspection classified as "no action indicated" with "zero Form-483 observations"

** Zero Form-483 observations indicate the facility is in acceptable state of compliance with current good manufacturing practices

** Stock up about 17% this week, on course for best weekly performance since September 2023 - NSE data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

** Shares of Wanbury Ltd WANB.NS rise as much as 5%, before trimming gains to trade 4.2% higher

** Pharma co said United States Food and Drug Administration completed inspection at co's Patalganga site in Maharashtra with zero observations

** Stock set for best one-day rise in a month

** Stock set to rise for a fifth straight quarter, gaining nearly 4x in the last four quarters

** Trading vol is 1.5x the 30-day daily avg

** Stock up ~31% in 2024 so far, after gaining 2.5x in 2023

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected] ;))

May 16 (Reuters) - Wanbury Ltd WANB.NS:

• WANBURY LTD MARCH-QUARTER CONSOL PAT 336.3 MILLION RUPEES VERSUS 10.2 MILLION RUPEES

• WANBURY LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.39 BILLION RUPEES VERSUS 1.33 BILLION RUPEES

Source text for Eikon: ID:nNSEzHxMk

Further company coverage: WANB.NS

(([email protected];;))

Oct 20 (Reuters) - Wanbury Ltd WANB.NS:

• INDIA'S WANBURY LTD SEPT-QUARTER CONSOL PAT 73.6 MILLION RUPEES VERSUS LOSS 8.9 MILLION RUPEES YEAR AGO

• WANBURY LTD SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.44 BILLION RUPEES VERSUS 1.24 BILLION RUPEES YEAR AGO

• WANBURY LTD - APPROVED ISSUE OF CONVERTIBLE WARRANTS WORTH UPTO 240 MILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: WANB.NS

(([email protected];))

Oct 17 (Reuters) - Wanbury Ltd WANB.NS:

• TO CONSIDER RAISING OF FUNDS

Source text for Eikon: ID:nBSEbV0Sf3

Further company coverage: WANB.NS

(([email protected];))

Aug 11 (Reuters) - Wanbury Ltd WANB.NS:

• INDIA'S WANBURY JUNE-QUARTER CONSOL PAT 46.9 MILLION RUPEES VERSUS LOSS 72.4 MILLION RUPEES

• WANBURY JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.46 BILLION RUPEES VERSUS 1.17 BILLION RUPEES

Source text for Eikon: ID:nBSE9qKvsj

Further company coverage: WANB.NS

(([email protected];;))

July 6 (Reuters) - Wanbury Ltd WANB.NS:

• TO CONSIDER ISSUE OF NONCONVERTIBLE DEBENTURES ON PRIVATE PLACEMENT BASIS

Source text for Eikon: ID:nBSE3Kv3vR

Further company coverage: WANB.NS

(([email protected];))